Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

ABSTRACT: Microscopic image source data list for Fig 4F and EV4 (Manuscript ID: EMM-2025-23148-T).

SUBMITTER: Subha Baniya

PROVIDER: S-BIAD2997 | bioimages |

REPOSITORIES: bioimages

ACCESS DATA

Json Xml

Similar Datasets

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

Project description: Not available

| S-SCDT-10_1038-S44321-026-00421-9 | biostudies-other

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

Project description: Not available

| S-BSST2770 | biostudies-other

Macrophages with cellular backpacks for targeted drug delivery to the brain.

Project description: Not available

| S-EPMC5605925 | biostudies-literature

Targeted Cellular Micropharmacies Deliver Therapeutic Agents to the Brain

Project description:The systemic administration of therapeutic agents, particularly large, charged molecules such as antibodies, has limited efficacy in treating central nervous system (CNS) disorders. In addition, the slow progression of neurodegenerative diseases makes repeated intrathecal injections unfeasible. Alzheimer’s disease is characterized by the accumulation of Aβ amyloid plaques. Microglia contribute to the clearance of Aβ, but are inhibited by the expression of CD33. Therefore, antibody blocking of CD33 may enhance the phagocytosis of Aβ by microglial cells, slowing AD progression. Here, we use cells as “targeted cellular micropharmacies” that are retained in the CNS to deliver therapeutic proteins directly into the brain. To achieve this, we genetically engineered CD4 T-cells to express: (1) a chimeric antigen receptor against GD2 to retain the cells into the brain, (2) ectopic FoxP3 to reduce inflammation, (3) secreted IL-2 to promote cell longevity, and (4) secreted anti-CD33 scFv antibody. Our proof-of-concept demonstrates that therapeutic antibodies can be delivered to the brain for at least 8 weeks to treat neurological disorders. Other agents could be similarly delivered into the brain by this platform.

2026-03-17 | GSE321698 | GEO